World News: 13:30 GMT Friday 9th November 2018. [Caladrius Biosciences, Inc. via Globe Newswire via SPi World News]
Basking Ridge, NJ, Nov. 09, 2018 (GLOBE NEWSWIRE) --
Date & Time: Wednesday, November 14 at 10:30 a.m. GMT, Adelphia 2Presenter: David J. Mazzo, PhD, President and Chief Executive Officer
Venue: Waldorf Hilton, Aldwych, London WC2B 4DD
Caladrius is a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. The Company’s goal is to build a broad portfolio of novel and versatile products that address important unmet medical needs. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34 cell therapy platform: CLBS12, recipient of SAKIGAKE designation, in Phase 2 testing in Japan and eligible for early conditional approval for the treatment of critical limb ischemia; CLBS14-CMD, in Phase 2 testing for the treatment of coronary microvascular dysfunction and CLBS14-RfA in late-stage development for refractory angina for which it has received RMAT designation. Caladrius’ autoimmune product candidate in Phase 2 testing, CLBS03, is an expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes. CLBS03 has been awarded Fast Track and Orphan designations by the FDA. For more information on the company, please visit .
Investors and Media:Caladrius Biosciences, Inc.John MendittoExecutive Director, Investor Relations and Corporate CommunicationsPhone: +1-908-842-0084Email:
# # #
Globe Newswire: 13:30 GMT Friday 9th November 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.